Endoglin for targeted cancer treatment.

Curr Oncol Rep

Hematology-Oncology, UCLA Medical Center Santa Monica, 2020 Santa Monica Blvd, Ste 600, Santa Monica, CA, 90404, USA,

Published: February 2014

AI Article Synopsis

  • Endoglin is a critical receptor involved in angiogenesis, especially in endothelial cells during low oxygen conditions, and its expression can affect resistance to VEGF-targeted therapies.
  • TRC105, an antibody that inhibits endoglin, shows promise in enhancing the effectiveness of VEGF therapies like bevacizumab and is currently being tested in randomized clinical trials.
  • Ongoing research includes exploring TRC105 in combination with other treatments for various cancers and stratifying soft tissue sarcoma patients based on endoglin levels to optimize treatment outcomes.

Article Abstract

Endoglin is a homodimeric cell membrane glycoprotein receptor for transforming growth factor β and bone morphogenetic proteins. Endoglin is essential for angiogenesis, being densely expressed on proliferating endothelial cells and upregulated during hypoxia. Its expression is implicated in development of resistance to vascular endothelial growth factor (VEGF) inhibition. TRC105 is an antibody that binds endoglin and prevents endothelial cell activation. Targeting endoglin and the VEGF pathway concurrently improves treatment in vitro and appears to reverse resistance to bevacizumab in some refractory cancer patients. Randomized trials are under way to assess the clinical benefit of adding TRC105 therapy to bevacizumab therapy. Further trials are under way to assess the activity of TRC105 with small-molecule inhibitors of the VEGF pathway in renal cell carcinoma, hepatocellular carcinoma, and soft tissue sarcoma. Stratification of soft tissue sarcomas based on endoglin expression levels is proposed to identify patients most likely to benefit from TRC105 treatment. The development of a TRC105 antibody-drug conjugate is also described.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-013-0365-xDOI Listing

Publication Analysis

Top Keywords

growth factor
8
vegf pathway
8
trials assess
8
soft tissue
8
endoglin
6
trc105
5
endoglin targeted
4
targeted cancer
4
cancer treatment
4
treatment endoglin
4

Similar Publications

Objective: Tuberous sclerosis complex (TSC) is a monogenetic disorder associated with sustained mechanistic target of rapamycin (mTOR) activation, leading to heterogeneous clinical manifestations. Epilepsy and renal angiomyolipoma are the most important causes of morbidity in adult people with TSC (pwTSC). mTOR is a key player in inflammation, which in turn could influence TSC-related clinical manifestations.

View Article and Find Full Text PDF

Vaccinia growth factor-dependent modulation of the mTORC1-CAD axis upon nutrient restriction.

J Virol

January 2025

Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.

The molecular mechanisms by which vaccinia virus (VACV), the prototypical member of the poxviridae family, reprograms host cell metabolism remain largely unexplored. Additionally, cells sense and respond to fluctuating nutrient availability, thereby modulating metabolic pathways to ensure cellular homeostasis. Understanding how VACV modulates metabolic pathways in response to nutrient signals is crucial for understanding viral replication mechanisms, with the potential for developing antiviral therapies.

View Article and Find Full Text PDF

Treatment with antibiotics is a major risk factor for infection, likely due to depletion of the gastrointestinal microbiota. Two microbiota-mediated mechanisms thought to limit colonization include the conversion of conjugated primary bile salts into secondary bile salts toxic to growth and competition between the microbiota and for limiting nutrients. Using a continuous flow model that simulates the nutrient conditions of the distal colon, we investigated how treatment with 6 clinically used antibiotics influenced susceptibility to infection in 12 different microbial communities cultivated from healthy individuals.

View Article and Find Full Text PDF

Antagonisation of Prokineticin Receptor-2 Attenuates Preeclampsia Symptoms.

J Cell Mol Med

January 2025

Interdisciplinary Research Institute of Grenoble, IRIG-Biosanté, University Grenoble Alpes, INSERM, CEA, UMR 1292, Grenoble, France.

Preeclampsia (PE) is the most threatening pathology of human pregnancy. Placenta from PE patients releases harmful factors that contribute to the exacerbation of the disease. Among these factors is the prokineticin1 (PROK1) and its receptor, PROKR2 that we identified as a mediators of PE.

View Article and Find Full Text PDF

Stress-induced plant volatiles play an important role in mediating ecological interactions between plants and their environment. The timing and location of the inflicted damage is known to influence the quality and quantity of induced volatile emissions. However, how leaf characteristics and herbivore feeding behaviour interact to shape volatile emissions is not well understood.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!